Biocept Secures Agreement with FedMed
FedMed was founded in 2000 with corporate headquarters located in
"With the expansion and progress in precision medicine and molecular diagnostic testing, we are pleased to offer
"Our highly sensitive and highly specific assays that can profile cancer-associated biomarkers from a blood sample demonstrate a clear advancement in the move to precision medicine," said
"Our Target Selector™ assays may provide biomarker status information that was previously not available due to inadequate tissue samples. These patients are often too sick to obtain the necessary tissue using a surgical biopsy method," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the potential of our diagnostic
assays to improve the detection and treatment of cancer and our plans to introduce
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-secures-agreement-with-fedmed-300232835.html
SOURCE
News Provided by Acquire Media